# US 2008/0188478 A1 · Compounds Useful In Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188478 A1
- Document ID: US20080188478A1
- Status: Published application
- Kind: A1
- Application number: 11/912,592
- Filed: 2006-04-18
- Published: 2008-08-07
- Earliest claimed: 2005-04-26
- Assignees: Pfizer Inc.
- Inventors: Justin Stephen Bryans; Mark Edward Bunnage; Patrick Stephen Johnson; Helen Janet Mason; Lee Richard Roberts; Thomas Ryckmans; Alan Stobie; Toby James Underwood
- Web page: https://patentgrep.com/patent/US20080188478A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents a group selected from H, CF3, and C1-6 alkyl (optionally substituted by C1-6 alkyloxy or triazolyl); R2 represents halo; Ring A represents a 5- or 6-membered heterocyclic ring containing at least one N atom (the ring being optionally bridged with two or more carbon atoms); R3 represents a 5- or 6-membered heterocyclic ring containing at least one atom selected from N, O or S, the heterocyclic ring being optionally substituted by one or more groups selected from C1-6 alkyl oxo or NH2, the heterocyclic ring being further optionally fused to a 5- or 6-membered aryl or heterocyclic ring containing at least one atom selected from N, O or S, the fused aryl or heterocyclic ring being substituted by one or more halo atoms; are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhea.

## Claims

### Claim at position 1

-21. (canceled)

### Claim 22

A compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a group selected from H, trifluoromethyl, and C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted by C1-6 alkyloxy or triazolyl;
R2 is halo;
Ring A is a 5- or 6-membered heterocyclic ring containing one to three N atoms and wherein the ring is optionally bridged with two to five carbon atoms; and
R3 is a 5- or 6-membered heterocyclic ring containing one to four atoms selected from N, O and S, the heterocyclic ring being optionally substituted by one to four groups selected from C1-6 alkyl, oxo and NH2, the heterocyclic ring being further optionally fused to a 5- or 6-membered aryl or heterocyclic ring containing one to four atoms selected from N, O and S, the fused aryl or heterocyclic ring being optionally substituted by one to four halo atoms.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R1 is methyl, trifluoromethyl, methoxymethyl, or triazolyl-methyl; or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R2 is chloro; or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 22)

The compound of claim 22, wherein ring A is piperidinyl or piperazinyl; or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 22)

The compound of claim 22, wherein R3 is a 5- or 6-membered heterocyclic ring containing one to four atoms selected from N, O or S, the heterocyclic ring being optionally substituted by one to four groups selected from C1-6 alkyl, oxo and NH2, the heterocyclic ring being fused to a 5- or 6-membered aryl or heterocyclic ring containing one to four atoms selected from N, O or S, the fused aryl or heterocyclic ring being substituted by one to two halo atoms; or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The compound of claim 26, wherein R1 is a 5- or 6-membered heterocyclic ring containing one to four atoms selected from N, O or S, the heterocyclic ring being optionally substituted by one to four groups selected from C1-6 alkyl, oxo and NH2, the heterocyclic ring being fused to a phenyl or pyridyl ring, the phenyl or pyridyl ring being substituted by one to two halo atoms; or a pharmaceutically acceptable salt thereof.

### Claim 28

The compound of 27, wherein R3 is:
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 22)

The compound of claim 22 selected from
1-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-2-methyl-1H-benzimidazole;
1-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
1-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-3-methyl-1,3-dihydro-2H-benzimidazol-2-one;
5-chloro-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
1-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-5-fluoro-1,3-dihydro-2H-benzimidazol-2-one;
1-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-1H-1,2,3-benzotriazole;
3-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}[1,3]oxazolo[4,5-b]pyridin-2(3H)-one;
3-{1-[4(4-chlorophenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]piperidin-4-yl}[1,3]oxazolo[4,5-b]pyridin-2(3H)-one;
1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidine;
4-{1-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one;
1-[4-(4-chlorophenyl)-5-methyl-44-1,2,4-triazol-3-yl]-4-(5-isopropyl-1,2,4-oxadiazol-3-yl)piperidine;
1-[4-(4-chlorophenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-4-(5-isopropyl-1,2,4-oxadiazol-3-yl)piperidine;
3-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}[1,2,4]triazolo[4,3-b]pyridazine;
3-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;
3-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-3H-imidazo[4,5-b]pyridine;
3-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-3H-[1,2,3]triazolo[4,5-b]pyridine;
1-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-1H-benzimidazol-2-amine;
1-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-3-methyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide;
3-{1-[4-(4-Chlorophenyl)-5-methyl)-4H-1,2,4-triazol-3-yl]piperidin-4-yl}-6-fluoro-3H-[1,2,3]triazolo[4,5-b]pyridine;
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperazin-1-yl}-1,2-benzisothiazole;
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperazin-1-yl}-1,2-benzisothiazole 1,1-dioxide;
3-{4-[4-(4-Chlorophenyl)-5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]piperazin-1-yl}-1,2-benzisothiazole;
3-{4-[4-(4-Chlorophenyl)-5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]piperazin-1-yl}-1,2-benzisothiazole 1,1-dioxide;
3-{(3-endo)-8-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-3H-imidazo[4,5-c]pyridine;
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}-1,2-benzisothiazole;
3-{4-[4-(4-Chlorophenyl)-5-(methoxymethyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}-1,2-benzisothiazole;
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}isothiazolo[5,4-b]pyridine;
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}-1,2-benzisothiazole 1,1-dioxide; and
3-{4-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}isoxazolo[4,5-b]pyridine;
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 22)

A method of treating anxiety, cardiovascular disease, primary dysmenorrhea, secondary dysmenorrhea, endometriosis, emesis, intrauterine growth retardation, inflammation, mittlesmerchz, preclampsia, premature ejaculation, premature labor or Raynaud's disease in a mammal, the method comprising administering to the mammal in need of treatment thereof a therapeutically effective amount of a compound of claim 22.

### Claim 31 (depends on 30)

The method of claim 30, wherein the disorder is primary dysmenorrhea or secondary dysmenorrhea.

### Claim 32 (depends on 30)

The method of claim 30, wherein the disorder is anxiety.

### Claim 33 (depends on 22)

A pharmaceutical composition comprising a compound of claim 22 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 34 (depends on 22)

A pharmaceutical composition comprising a combination of: (A) a compound according to claim 22; and (B) an additional pharmacologically active ingredient.

### Claim 35 (depends on 34)

The composition of claim 34, wherein (B) is an oral contraceptive, PDEV inhibitor, COX inhibitor, NO-donor or L-arginine.

### Claim 36 (depends on 35)

A method of treating primary dysmenorrhea or secondary dysmenorrhea, the method comprising administering to a patient in need of such treatment a combination of amounts of (A) and (B) according to claim 35, which are together effective in treating primary dysmenorrhea or secondary dysmenorrhea.
